久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

US Drugmaker Trevena’s Ultra-Strong Painkiller Begins Final-Stage Trials in China

firstwordpharmaJuly 08, 2021

Tag: Trevena , TRV-130 , FDA

Treneva's TRV-130 has entered Phase III trials in China, as reported Yicai Global on Wednesday.

TRV-130, which was approved by the FDA last year, is used to treat moderate to severe acute pain in adults.

The company's Chinese partner Jiangsu Nhwa Pharmaceutical said that tests have begun on the first volunteer in trials at the Third Xiangya Hospital of Central South University in Changsha, central Hunan province.


Previous:Stealth BioTherapeutics Joins the Rare Disease Company Coalition

Next:Absci Strengthens Executive Leadership Team

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service